Overview

Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis

Status:
Completed
Trial end date:
2017-05-24
Target enrollment:
Participant gender:
Summary
This two cohort study (Cohort A and B) is being conducted to assess the safety and efficacy of BBI-2000 for the prevention (Cohort A) and treatment (Cohort B) of delayed type hypersensitivity reaction.
Phase:
Phase 1
Details
Lead Sponsor:
Brickell Biotech, Inc.